Literature DB >> 29384146

Immunotherapy: Targeting MDSCs with LXR agonists.

David Killock.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29384146     DOI: 10.1038/nrclinonc.2018.17

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.

Authors:  Masoud F Tavazoie; Ilana Pollack; Raissa Tanqueco; Benjamin N Ostendorf; Bernardo S Reis; Foster C Gonsalves; Isabel Kurth; Celia Andreu-Agullo; Mark L Derbyshire; Jessica Posada; Shugaku Takeda; Kimia N Tafreshian; Eric Rowinsky; Michael Szarek; Roger J Waltzman; Elizabeth A Mcmillan; Connie Zhao; Monica Mita; Alain Mita; Bartosz Chmielowski; Michael A Postow; Antoni Ribas; Daniel Mucida; Sohail F Tavazoie
Journal:  Cell       Date:  2018-01-11       Impact factor: 41.582

  1 in total
  1 in total

Review 1.  Molecular imaging for cancer immunotherapy.

Authors:  E A Lim; C G Drake; A Mintz
Journal:  Immunooncol Technol       Date:  2020-03-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.